Transient prenatal ruxolitinib treatment suppresses astrogenesis during development and improves learning and memory in adult mice.

ABSTRACT: Ruxolitinib is the first janus kinase 1 (JAK1) and JAK2 inhibitor that was approved by the United States Food and Drug Administration (FDA) agency for the treatment of myeloproliferative neoplasms. The drug targets the JAK/STAT signalling pathway, which is critical in regulating the gliogenesis process during nervous system development. In the study, we assessed the effect of non-maternal toxic dosages of ruxolitinib (0-30 mg/kg/day between E7.5-E20.5) on the brain of the developing mouse embryos. While the pregnant mice did not show any apparent adverse effects, the Gfap protein marker for glial cells and S100β mRNA marker for astrocytes were reduced in the postnatal day (P) 1.5 pups' brains. Gfap expression and Gfap⁺ cells were also suppressed in the differentiating neurospher

SUBMITTER: Lee HC 

PROVIDER: S-EPMC7884429 | biostudies-literature | 2021 Feb

REPOSITORIES: biostudies-literature